Non-steroidal mineralocorticoid receptor antagonists in heart failure

被引：0
作者：
Filippatos, Gerasimos [1 ]
Farmakis, Dimitrios [1 ]
机构：
[1] Natl & Kapodistrian Univ, Athens Univ Hosp Attikon, Athens Med Sch, Dept Cardiol, Athens, Greece
来源：
NATURE REVIEWS CARDIOLOGY | 2023年
关键词：
CHRONIC KIDNEY-DISEASE; FINERENONE;
D O I：
10.1038/s41569-023-00922
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Novel non-steroidal mineralocorticoid receptor antagonists (MRAs) have improved pharmacological properties compared with steroidal MRAs. Among the non-steroidal MRAs, finerenone has been approved for patients with chronic kidney disease who have diabetes mellitus and has demonstrated favourable safety and promising early results in patients with heart failure.
引用
收藏
页数：2
相关论文
共 10 条
  • [1] Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
    Agarwal, Rajiv
    Kolkhof, Peter
    Bakris, George
    Bauersachs, Johann
    Haller, Hermann
    Wada, Takashi
    Zannad, Faiez
    [J]. EUROPEAN HEART JOURNAL, 2021, 42 (02) : 152 - 161
  • [2] Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
    Agarwal, Rajiv
    Filippatos, Gerasimos
    Pitt, Bertram
    Anker, Stefan D.
    Rossing, Peter
    Joseph, Amer
    Kolkhof, Peter
    Nowack, Christina
    Gebel, Martin
    Ruilope, Luis M.
    Bakris, George L.
    [J]. EUROPEAN HEART JOURNAL, 2022, 43 (06) : 474 - +
  • [3] Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
    Bakris, George L.
    Agarwal, Rajiv
    Anker, Stefan D.
    Pitt, Bertram
    Ruilope, Luis M.
    Rossing, Peter
    Kolkhof, Peter
    Nowack, Christina
    Schloemer, Patrick
    Joseph, Amer
    Filippatos, Gerasimos
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (23) : 2219 - 2229
  • [4] Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction
    Butler, Javed
    Packer, Milton
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Zeller, Cordula
    Schnee, Janet
    Brueckmann, Martina
    Pocock, Stuart J.
    Zannad, Faiez
    Anker, Stefan D.
    [J]. EUROPEAN HEART JOURNAL, 2022, 43 (05) : 416 - 426
  • [5] Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial
    Filippatos, Gerasimos
    Pitt, Bertram
    Agarwal, Rajiv
    Farmakis, Dimitrios
    Ruilope, Luis M.
    Rossing, Peter
    Bauersachs, Johann
    Mentz, Robert J.
    Kolkhof, Peter
    Scott, Charlie
    Joseph, Amer
    Bakris, George L.
    Anker, Stefan D.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (06) : 996 - 1005
  • [6] Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial
    Filippatos, Gerasimos
    Anker, Stefan D.
    Agarwal, Rajiv
    Ruilope, Luis M.
    Rossing, Peter
    Bakris, George L.
    Tasto, Christoph
    Joseph, Amer
    Kolkhof, Peter
    Lage, Andrea
    Pitt, Bertram
    [J]. CIRCULATION, 2022, 145 (06) : 437 - 447
  • [7] A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
    Filippatos, Gerasimos
    Anker, Stefan D.
    Boehm, Michael
    Gheorghiade, Mihai
    Kober, Lars
    Krum, Henry
    Maggioni, Aldo P.
    Ponikowski, Piotr
    Voors, Adriaan A.
    Zannad, Faiez
    Kim, So-Young
    Nowack, Christina
    Palombo, Giovanni
    Kolkhof, Peter
    Kimmeskamp-Kirschbaum, Nina
    Pieper, Alexander
    Pitt, Bertram
    [J]. EUROPEAN HEART JOURNAL, 2016, 37 (27) : 2105 - 2114
  • [8] McDonagh TA, 2021, EUR HEART J, V42, DOI [10.1093/eurheartj/ehab670, 10.1093/eurheartj/ehab368]
  • [9] Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
    Pitt, Bertram
    Filippatos, Gerasimos
    Agarwal, Rajiv
    Anker, Stefan D.
    Bakris, George L.
    Rossing, Peter
    Joseph, Amer
    Kolkhof, Peter
    Nowack, Christina
    Schloemer, Patrick
    Ruilope, Luis M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (24) : 2252 - 2263
  • [10] Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
    Pitt, Bertram
    Kober, Lars
    Ponikowski, Piotr
    Gheorghiade, Mihai
    Filippatos, Gerasimos
    Krum, Henry
    Nowack, Christina
    Kolkhof, Peter
    Kim, So-Young
    Zannad, Faiez
    [J]. EUROPEAN HEART JOURNAL, 2013, 34 (31) : 2453 - 2463
1